Alcon gets buy rating on Tryptyr launch in dry eye market, backed by strong R&D and financials.

Alcon has been given a buy rating driven by the launch of Tryptyr, a new treatment for dry eye disease with a unique mechanism that boosts tear production quickly. The drug's commercial success will depend on factors like refill rates, insurance coverage, and patient adherence. Alcon's strong commercial presence and solid financial position support ongoing research, acquisitions, dividends, and share buybacks, reducing financing risks. Key risks include insurance restrictions, patient tolerance, competition, and potential slower growth after 2026.